Study S000200

Tirzepatide Study of Renal Function in People With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes: Focus on Kidney Hypoxia in Relation to Fatty Kidney Disease Using Multiparametric Magnetic Resonance Imaging

ClinicalTrials.gov record

Registration

Registration: NCT05536804
Acronym: TREASURE-CKD
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 134
Start: 2023-02-08
Primary completion: 2026-07-06
Lead sponsor: Eli Lilly and Company
Conditions: Overweight; Obesity; Chronic Kidney Disease; Type 2 Diabetes; T2D
Interventions: DRUG:Tirzepatide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:I8F-MC-GPIG; EUDRACT_NUMBER:2021-005273-47; OTHER:2023-506082-60-00; NIH:2023

Registered primary outcomes

Percent Change from Baseline in Renal Sinus Fat Content (MRI) [Baseline, Week 52]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0010237	Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes. Natale P, The Cochrane database of systematic reviews	2025	Systematic review	PMID 39963952 DOI	cites ClinicalTrials.gov:NCT05536804; registry reference DERIVED:39963952
R0016891	Kidney Parameters with Tirzepatide in Obesity with or without Type 2 Diabetes. Heerspink HJL, Journal of the American Society of Nephrology : JASN	2025	Randomized trial	PMID 40512543 DOI	cites ClinicalTrials.gov:NCT05536804; registry reference DERIVED:40512543